Category: Biotherapeutic Index

  • Neurexan®

    • DROPS · TABLETS

    Compositions:
    Drops: 100 g containing: Passiflora incarnata D2, Avena sativa D2, Coffea arabica D12, Zincum isovalerianicum D4 0.06 g each. Contains 36 vol.-% alcohol.
    Tablets: 1 tablet containing: Passiflora incarnata D2, Avena sativa D2, Coffea arabica D12, Zincum isovalerianicum D4 0.6 mg each.

    Indications: Nervous restlessness and sleep disturbances.
    Contraindications: Known allergy (hypersensitivity) to one or more of the ingredients.
    Side effects: Due to the homeopathic nature of Neurexan drops/tablets a temporary worsening in symptoms (initial aggravation) is possible but harmless. Tablets: Allergic (hypersensitivity) skin reactions may occur in very rare cases (i.e. affects less than 1 in 10,000 users).
    Interactions with other medication: None known.

    Dosage:
    Drops: Standard dosage: Adults and children 12 yrs. and older): 10 drops 3x daily. Acute or initial dosage: Adults (and children 12 yrs. and older): 10 drops every ½ to 1 hr., up to 12x daily, and then continue with standard dosage.
    Tablets: Standard dosage: Adults and children 12 yrs. and older): 1 tablet to be dissolved in the mouth 3x daily. Acute or initial dosage: Adults (and children 12 yrs. and older): 1 tablet every ½ to 1 hr., up to 12x daily, and then continue with standard dosage.

    Package sizes:
    Drops: Drop bottles containing 30 and 100 ml. (9880)
    Tablets: Packs containing 50 and 250 tablets. (9519)

    Pharmacological notes

    Passiflora incarnata: insomnia¹–⁹ and nervousness²,⁴–⁷,¹³

    Avena sativa: insomnia¹,⁵,⁸–¹⁰,¹¹ and nervousness¹,²,⁵,¹¹,¹³,¹⁴

    Coffea arabica: insomnia¹,⁴,⁶,¹⁰,¹²,¹⁵–²⁰ nervousness²,³,¹⁰,¹⁵,²¹–²⁸ irritability²,¹⁰,¹⁵,²⁵,²⁹ and restlessness²,⁶,⁸,¹⁵,²¹,³⁰–³²

    Zincum isovalerianicum: insomnia¹,⁶ and nervousness¹,⁶–⁸,¹²–¹⁵,²³,³³

    Clinical notes

    Because of the individual constituents of Neurexan, the medication can be offered for the following conditions:

    1. Nervousness or nervous restlessness. Empirically, in this condition, Neurexan is fast in onset and can be taken when necessary. This includes nervousness associated with overuse of coffee and other stimulants.
    2. Insomnia. Empirically, the best results are achieved after continuous use over a few weeks to restore the sleep pattern, although Neurexan will induce sleep when taken as necessary.
    3. Irritability and restlessness.

    References

    1. Blackwood A.L. A Manual of Materia Medica, Therapeutics and Pharmacology (With Clinical Index). 2nd ed. New Delhi, India: World Homeopathic Links; 1982.
    2. Boericke W. Pocket Manual of Homoeopathic Materia Medica With Repertory, Comprising the Characteristic and Guiding Symptoms of All Remedies. 6th ed. Santa Rosa, CA: Boericke & Tafel; 1927.
    3. Choudhuri NM. A Study on Materia Medica and Repertory. 2nd ed. New Delhi, India: Jain Publishers Ltd; 1929.
    4. Lippe A. Keynotes and Red Line Symptoms of Materia Medica. New Delhi, India: Jain Publishers Ltd; 1998.
    5. Mohanty N. Text-Book of Homoeopathic Materia Medica. 1st ed. New Delhi, India: Jain Publishers Ltd; 1997.
    6. Murphy R. Homoeopathic Medical Repertory: A Modern Alphabetical Repertory. 1st ed. Pagosa Springs, CO: Hahnemann Academy of North America; 1993.
    7. Murphy R. The Homoeopathic Remedy Guide: 1200 Homeopathic and Herbal Remedies. 1st ed. Blacksburg, VA: HANA Press; 2000.
    8. Phatak SR. Materia Medica of Homoeopathic Medicines. 1st ed. London, England: Fowler-Vaughan Publishers; 1988.
    9. Vermeulen F. Concordant Materia Medica. 2nd ed. Haarlem, the Netherlands: Merlijn Publishers; 1997.
    10. Clarke JH. A Dictionary of Practical Materia Medica. Vol 1-3. 3rd ed. Bradford, England: Health Science Press; 1977.
    11. Gupta RL. Directory of Diseases and Cures in Homoeopathy: 1500 Authoritative References With Causes & Symptoms. Vol 1-2. 1st ed. New Delhi, India: Jain Publishers Ltd; 1989.
    12. Lilienthal S. Homoeopathic Therapeutics. 5th ed. Calcutta, India: Sett Dev & Co; 1925.
    13. Schroyens F. Synthesis: Repertorium Homeopathicum Syntheticum. 9th ed. London, England: Homeopathic Book Publishers; 2004.
    14. Dewey WA. Practical Homeopathic Therapeutics. 3rd ed. Philadelphia, PA: Boericke & Tafel; 1934.
    15. Burt WH. Physiological Materia Medica. 5th ed. Chicago, IL: Gross & Delbridge; 1896.
    16. Gibson DM. Studies of Homoeopathic Remedies. 1st ed. Beaconsfield, England: Beaconsfield Publishers Ltd; 1987.
    17. Morrison R. Desktop Companion to Physical Pathology. 1st ed. Albany, CA: Hahnemann Clinic Publishing; 1998.
    18. Boericke J. Homoeopathic Treatment of the Diseases of Heart. Mukerjee RK, trans-ed. New Delhi, India: World Homoeopathic Links; 1982.
    19. Rastogi DP. Homoeopathic Gems. 2nd ed. New Delhi, India: Jain Publishers Ltd; 1997.
    20. Vermeulen F. Prisma–The Arcana of Materia Medica Illuminated–Similars and Parallels Between Substance and Remedy. 2nd ed. Haarlem, the Netherlands: Emryss Publishers; 2002.
    21. Allen TF. Handbook of Materia Medica and Homeopathic Therapeutics. 1st ed. New Delhi, India: Jain Publishers Ltd; 1889.
    22. Allen TF. A Primer of Materia Medica for Practitioners of Homoeopathy. 1st ed. Philadelphia, PA: Boericke & Tafel; 1892.
    23. Boericke GM. A Synoptic Key of the Materia Medica. 1st ed. New Delhi, India: Jain Publishers Ltd; 1931.
    24. Buck H. The Outlines of Materia Medica and a Clinical Dictionary. 1st ed. New Delhi, India: Jain Publishers Ltd; 1865.
    25. Burt WH. Characteristic Materia Medica. 1st ed. New Delhi, India: Jain Publishers Ltd; 1978.
    26. Cleveland CL. Salient Materia Medica and Therapeutics. 1st ed. New Delhi, India: Jain Publishers Ltd; 1888.
    27. Farrington EA. Lesser Writings With Therapeutic Hints. 1st ed. Calcutta, India: Sizer & Co; 1935.
    28. Farrington EA. A Clinical Materia Medica Being a Course of Lectures Delivered at the Hahnemann Medical College, of Philadelphia. 2nd ed. Philadelphia, PA: Hahnemann Publishing House; 1890.
    29. Hering C. The Guiding Symptoms of Our Materia Medica. Vol 1-10. 1st ed. New Delhi, India: Jain Publishers Ltd; 1989.
    30. Allen HC. The Therapeutics of Intermittent Fever. 2nd ed. New Delhi, India: Jain Publishers Ltd; 1884.
    31. Allen TF. The Encyclopedia of Pure Materia Medica: A Record of the Positive Effects of Drugs Upon the Healthy Human Organism. Vol 1-12. 1st ed. Ridgewood, NJ: Gregg Press; 1964.
    32. Royal G. Textbook of Homeopathic Materia Medica. 1st ed. Calcutta, India: Roy Publishing House; 1920.
    33. Hale EM. Special Symptomatology of the New Remedies. New Delhi, India: Jain Publishers Ltd.

  • Thyreoi­dea compositum

    DROPS · INJECTION SOLUTION

    Compositions:
    Drops: 100 g containing: Glandula thyreoidea suis D8, Thymus suis D10, Splen suis D10, Medulla ossis suis D10, Funiculus umbilicalis suis D10, Hepar suis D10, Galium aparine D4, Sedum acre D6, Sempervivum tectorum ssp. tectorum D6, Conium maculatum D4, Euspongia officinalis D8, Acidum sarcolacticum D4, Fucus vesiculosus D6, Calcium fluoratum D10, Colchicum autumnale D4, Viscum album D3, Cortisonum aceticum D28, Pulsatilla pratensis D8, Sulfur D10, Natrium diethyl­oxalaceticum D8, Acidum fumaricum D8, Acidum DL-malicum D8, Acidum alpha -ketoglutaricum D8, Adenosinum triphosphoricum D8 4 g each. Contains 35 vol.-% alcohol.
    Injection solution: 2.2 ml containing: Glandula thyreoidea suis D8, Thymus suis D10, Splen suis D10, Medulla ossis suis D10, Funiculus umbilicalis suis D10, Hepar suis D10, Galium aparine D4, Sedum acre D6, Sempervivum tectorum ssp. tectorum D6, Conium maculatum D4, Euspongia officinalis D8, Acidum sarcolacticum D3, Fucus vesiculosus D6, Calcium fluoratum D10, Colchicum autumnale D4, Viscum album D3, Cortisonum aceticum D28, Pulsatilla pratensis D8, Sulfur D10, Natrium diethyl­oxalaceticum D8, Acidum fumaricum D8, Acidum DL-malicum D8, Acidum alpha-ketoglutaricum D8, Adenosinum triphosphoricum D8 22 mg each.

    Indications:
    Stimulation of the defense system in connective tissue, thyroid and other glandular dysfunctions.

    Contraindications:
    Pregnancy and lactation. Viscum album containing products should not be used in persons with known allergies to mistletoe, in cases of chronic granulomatous and autoimmune diseases, and in cases of hyperthyroidism with an unbalanced metabolic condition. In acute inflammatory and highly feverish conditions, discontinue treatment until the inflammation and fever have disappeared.

    Side effects:
    A minor increase of body temperature, localized inflammatory reactions around the site where the subcutaneous injection was given as well as transient insignificant swellings of regional lymph nodes are harmless. Occasionally, veins may respond, presenting inflammatory irritative symptoms. A temporary interruption of the therapy will be necessary in that case. In the presence of an intolerance to mistletoe, there are rare cases where local or general allergic reactions or reactions similar to allergies, such as a generalized itchiness, urticaria, rash, swelling in the face (Quincke’s edema), shivering fits, dyspnea, sudden fall in blood pressure, shock, may occur; such reactions will require a discontinuation of the drug and an immediate medical treatment. In rare cases, an activation of inflammations may occur (eg, chronic sinusitis, apical granulomas).

    Interactions with other medication:
    None known.

    Dosage:
    Drops: Standard dosage: Adults (and children 12 yrs. and older): 10 drops 3x daily. Acute or initial dosage: Adults (and children 12 yrs. and older): 10 drops every ½ to 1 hr., up to 12x daily, and then continue with standard dosage.
    Injection solution: Standard dosage: Adults (and children 12 yrs. and older): 1 ampoule 1 to 3x weekly. Thyreoidea compositum injection solution may be administered by the s.c., i.d., i.m. or i.v. route.
    Acute or initial dosage: Adults (and children 12 yrs. and older): 1 ampoule daily, and then continue with standard dosage.

    Package sizes:
    Drops: Drop bottles containing 30 and 100 ml. (65812)
    Injection solution: Packs containing 10 and 100 ampoules of 2.2 ml each. (65908)

    Pharmacological notes
    Glandula thyreoidea suis: goiter, obesity-related cancerous conditions, and myxedema.¹˒²˒³
    Thymus suis: growth hormone disorders,¹˒³ cancerous conditions,¹˒² immune disorders, and lymphatic disorders.³
    Splen suis: anemia, leukemia, agranulocytosis,¹˒³ and immune deficiency.¹˒²
    Medulla ossis suis: anemic conditions, leukemia, agranulocytosis, coxitis, osteomalacia, chronic osteomyelitis, exostosis, arthritis deformans, and Morbus Sudeck.¹˒³
    Funiculus umbilicalis suis: chronic pathological features that involve the connective tissue.¹˒³
    Hepar suis: liver damage in general.¹˒³
    Galium aparine: cancer.⁴˒¹⁰
    Sedum acre: cancer.⁴˒⁹˒¹¹
    Sempervivum tectorum ssp. tectorum: cancer.⁴˒⁶˒¹²
    Conium maculatum: cancerous tendency,¹⁰˒¹³˒¹⁷ affected lymph glands,⁴˒⁵˒¹³˒¹⁸˒²⁷ and exhaustion.⁷˒⁸˒¹⁸˒²²˒²⁸˒³⁴
    Euspongia officinalis: lymphatic disorders,⁵˒⁸˒⁹˒¹¹˒¹⁶˒¹⁷˒²⁰˒³⁰˒³⁵˒³⁷ and hypertrophied thyroid glands.⁵˒⁷˒¹⁴˒¹⁸˒²¹˒²²˒²⁶˒²⁸˒³⁵˒³⁶˒³⁸˒⁴⁰
    Acidum sarcolacticum: painful cervical glands⁹˒¹⁰ and precancerous conditions.⁹˒¹¹˒⁴¹
    Fucus vesiculosus: thyroidal complaints and goiter.⁴˒⁸˒¹¹˒³⁹
    Calcium fluoratum: goiter,⁴˒⁷˒¹²˒²⁶˒³⁰˒⁴⁰ thyroiditis,⁴¹ and cancerous affections.⁸˒⁹˒²⁴
    Colchicum autumnale: goiter⁸ and gouty diathesis.⁴˒⁵˒⁹˒¹⁴˒¹⁸˒²⁰˒²¹˒²³˒²⁴˒²⁶˒²⁸˒³⁰˒³⁴˒³⁶˒³⁸˒⁴¹˒⁴²
    Viscum album: cancer.⁸˒⁹˒⁴¹
    Cortisonum aceticum: thyroidal complaints,⁹ goiter,¹¹˒⁴¹ damaged connective tissue,¹ and adrenal damage.¹˒³
    Pulsatilla pratensis: goiter,⁸ lymphatic disorders,⁸˒⁹˒²⁰˒²⁴˒³⁰˒³¹˒³⁵˒³⁶˒⁴³˒⁴⁵ and asthma.⁵˒¹⁵˒¹⁸˒²⁰˒²¹˒²⁸˒³⁰˒³¹˒³³˒³⁹˒⁴²˒⁴⁶˒⁴⁷
    Sulfur: goiter,⁸˒⁹˒²⁴˒³⁰ lymphatic disorders,⁵˒⁸˒⁹˒¹¹˒²¹˒³⁰˒³¹˒³⁶˒⁴³˒⁴⁸ scleroderma,⁸˒⁹˒⁴³ and asthma.⁵˒⁹˒¹⁰˒¹⁸˒²²˒²³˒³⁰˒³¹˒³⁴˒³⁶˒³⁸˒⁴²˒⁴⁷˒⁴⁹
    Natrium diethyl­oxalaceticum: asthma, cancerous conditions,¹ myopathia, and energy-deficit syndrome.³
    Acidum fumaricum: asthma, cancer, rheumatism,¹ and allergies of any kind.
    Acidum DL-malicum: asthma, precancerous conditions and neoplasma,¹ and rheumatic disorders.³
    Acidum alpha-ketoglutaricum: muscle and connective tissue disorders, soft tissue rheumatism,³ asthma, and precancerous conditions and neoplasma.¹
    Adenosinum triphosphoricum: cellular energy deficit¹˒³ and chronic fatigue syndrome.³

    Clinical notes
    Because of the individual constituents of Thyreoidea compositum, the medication can be offered for the following conditions:

    1. Adjunctive treatment in the dedifferentiation phases: precancerous conditions and frank neoplasms of various origins.
    2. Degenerative conditions: muscular dystrophy and arthrosis.
    3. Connective tissue dysfunction and disease: myxedema and scleroderma.
    4. Lymphatic disorders.
    5. Respiratory conditions: bronchial asthma.
    6. Gouty diathesis.

    Note:
    The unique formulation of Thyreoidea compositum makes it a medication with a broad application. It is especially useful for diseases classified on the right of the regulation/compensation division.

    References

    1. Reckeweg H-H. Homoeopathia Antihomotoxica: Symptomen-und Modalitätenverzeichnis mit Arzneimitteltherapie. Vol 1-2. 6th ed. Baden-Baden, Germany: Aurelia Verlag; 1999.
    2. Reinhart E. Suis-Organpräparate in der Homotoxikologie. 1st ed. Baden-Baden, Germany: Aurelia Verlag; 1994.
    3. Schmid F, Hamalick P. Antihomotoxische Medizin–Band II: Homöopathische Antihomotoxika. Vol 2. 1st ed. Baden-Baden, Germany: Aurelia Verlag; 1996.
    4. Boericke W. Pocket Manual of Homoeopathic Materia Medica With Repertory, Comprising the Characteristic and Guiding Symptoms of All Remedies. 9th ed. Santa Rosa, CA: Boericke & Tafel; 1927.
    5. Clarke JH. A Dictionary of Practical Materia Medica. Vol 1-3. 3rd ed. Bradford, England: Health Science Press; 1977.
    6. Hale EM. Special Symptomatology of the New Remedies. New Delhi, India: Jain Publishers Ltd; 1993.
    7. Lilienthal S. Homoeopathic Therapeutics. 5th ed. Calcutta, India: Sett Dey & Co.; 1925.
    8. Murphy R. Homeopathic Medical Repertory: A Modern Alphabetical Repertory. 1st ed. Pagosa Springs, CO: Hahnemann Academy of North America; 1993.
    9. Schroyens F. Synthesis: Repertorium Homeopathicum Syntheticum. 9th ed. London, England: Homeopathic Book Publishers; 2004.
    10. Vermeulen F. Concise Materia Medica. 2nd ed. Haarlem, the Netherlands: Merlijn Publishers; 1997.
    11. Murphy R. The Homeopathic Remedy Guide: 1200 Homeopathic and Herbal Remedies. 1st ed. Blacksburg, VA: HANA Press; 2000.
    12. Blackwood AL. A Manual of Materia Medica, Therapeutics and Pharmacology (With Clinical Index). 2nd ed. New Delhi, India: World Homoeopathic Links; 1922.
    13. Allen KC. Keynotes and Characteristics With Comparisons of Some of the Leading Remedies of the Materia Medica. 12st ed. Wellingborough, England: Thorsons Publishers Ltd; 1988.
    14. Douglas MAS. Pearls of Homeopathy. 1st ed. New Delhi, India: Jain Publishers Ltd; 1903.
    15. Mohanty N. Text-Book of Homoeopathic Materia Medica. 1st ed. New Delhi, India: Jain Publishers Ltd; 1997.
    16. Vermeulen F. Synoptic Materia Medica Vol. 1. 6th ed. Haarlem, the Netherlands: Merlijn Publishers; 2000.
    17. Vermeulen F. Prisma–The Arcana of Materia Medica Illuminated–Similars and Parallels Between Substance and Remedy. 2nd ed. Haarlem, the Netherlands: Emryss Publishers; 2002.
    18. Allen TF. Handbook of Materia Medica and Homeopathic Therapeutics. 1st ed. New Delhi, India: Jain Publishers Ltd; 1889.
    19. Allen TF. A Primer of Materia Medica for Practitioners of Homeopathy. 1st ed. Philadelphia, PA: Boericke & Tafel; 1892.
    20. Buck W. The Outlines of Materia Medica and a Clinical Dictionary. 1st ed. New Delhi, India: Jain Publishers Ltd; 1865.
    21. Burt WH. Characteristic Materia Medica. 1st ed. New Delhi, India: Jain Publishers Ltd; 1978.
    22. Cleveland CL. Standard Materia Medica and Therapeutics. 1st ed. New Delhi, India: Jain Publishers Ltd; 1982.
    23. Dewey WA. Physical Examination and Observations in Homoeopathy. 1st ed. Gent, Belgium: Homoeodon Boekservice; 1992.
    24. Dewey WA. Practical Homeopathic Therapeutics. 3rd ed. Philadelphia, PA: Boericke & Tafel; 1934.
    25. Dunham C. Homeopathy: The Science of Therapeutics (A Collection of Papers Elucidating and Illustrating the Principles of Homeopathy). 1st ed. Philadelphia, PA: Boericke & Tafel; 1871.
    26. Gupta DR. Dictionary of Diseases and Cures in Homoeopathy: 1500 Authoritative References With Causes & Symptoms. Vol 1-2. 1st ed. New Delhi, India: Jain Publishers Ltd; 1989.
    27. Hahnemann S. The Chronic Diseases, Their Peculiar Nature and Their Homeopathic Cure. Tafel LH, trans-ed. Vol 1-2. 2nd ed. New Delhi, India: Jain Publishers Ltd; 1981.
    28. Allen TF. The Encyclopedia of Pure Materia Medica: A Record of the Positive Effects of Drugs Upon the Healthy Human Organism. Vol 1-12. 1st ed. Ridgewood, NY: Gregg Press Inc.; 1964.
    29. Dunham C. Lectures on Materia Medica. 3rd ed. London, England, New York, NY, Philadelphia, PA: Boericke & Tafel; 1934.
    30. Hering C. The Guiding Symptoms of Our Materia Medica. Vol 1-10. 1st ed. New Delhi, India: Jain Publishers Ltd; 1989.
    31. Materia Medica–Synoptics. Vol 1-2. New Delhi, India: Jain Publishers Ltd; 1979.
    32. Kent JT. Lectures on Homoeopathic Materia Medica. 4th ed. London, England, New York, NY, Philadelphia, PA: Boericke & Tafel; 1946.
    33. Kulkarni S. Gynaecologic and Obstetric Therapeutics. 1st ed. New Delhi, India: Jain Publishers Ltd; 1994.
    34. Royal G. Textbook of Homoeopathic Materia Medica. 1st ed. Calcutta, India: Roy Publishing House; 1920.
    35. Burt WH. Physiological Materia Medica. 5th ed. Chicago, IL: Gross & Delbridge; 1896.
    36. Gibson DM. Studies of Homeopathic Remedies. 1st ed. Beaconsfield, England: Beaconsfield Publishers Ltd; 1987.
    37. Roberts HA. The Studies of Remedies by Comparison. 1st ed. New Delhi, India: Jain Publishers Ltd; 1979.
    38. Choudhuri NM. A Study on Materia Medica and Repertory. 2nd ed. New Delhi, India: Jain Publishers Ltd; 1929.
    39. Morrison R. Desktop Companion to Physical Pathology. 1st ed. Albany, CA: Hahnemann Clinic Publishing; 1990.
    40. Phatak SR. Materia Medica of Homoeopathic Medicines. 1st ed. London, England: Kolve-Vaughan Publishers; 1980.
    41. Julian OA. Materia Medica of New Homoeopathic Remedies. 1st ed. Beaconsfield, England: Beaconsfield Publishers Ltd; 1990.
    42. Boericke GA. A Synoptic Key of the Materia Medica. 1st ed. New Delhi, India: Jain Publishers Ltd; 1931.
    43. Farrington H. Homoeopathy and Homoeopathic Philosophy (Prepared for and Offered Only to Graduate Physicians). 1st ed. Philadelphia, PA: American Homeopathic Pub Co.; 1922.
    44. Farrington EA. Comparative Materia Medica. 3rd ed. New Delhi, India: Jain Publishers Ltd; 1983.
    45. Hughes R. Manual of Homoeopathic Pharmacodynamics. 5th ed. London, England: Leath & Ross; 1886.
    46. Hahnemann S. Materia Medica Pura. Vol 1-2. 1st ed. London, England: Homeopathic Book Publishers; 1880.
    47. Herscu P. The Homeopathic Treatment of Children: Pediatric Constitutional Types. 1st ed. Berkeley, CA: North Atlantic Books; 1991.
    48. Hughes R, Dake JP. A Cyclopaedia of Drug Pathogenesy. Vol 1-4. 1st ed. New Delhi, India: World Homoeopathic Links; 1891.
    49. Farrington EA. Lesser Writings With Therapeutic Hints. 1st ed. Calcutta, India: Salzer & Co; 1935.

  • Zeel®

    Compositions:

    Tablets: 1 tablet containing: Cartilago suis D4 0.3 mg, Funiculus umbilicalis suis D4 0.3 mg, Embryo totalis suis D4 0.3 mg, Placenta totalis suis D4 0.3 mg, Rhus toxicodendron D2 0.54 mg, Arnica montana D1 0.6 mg, Solanum dulcamara D2 0.15 mg, Symphytum officinale D8 0.15 mg, Sanguinaria canadensis D3 0.45 mg, Sulfur D6 0.54 mg, Nadidum D6 0.03 mg, Coenzyme A D6 0.03 mg, Natrium diethyloxalaceticum D6 0.03 mg, Acidum DL-alpha liponicum D6 0.03 mg, Acidum silicicum D6 3 mg.

    Injection solution: 1 ampoule of 2.0 ml (≈ 2.0 g) contains: Cartilago suis D6 2 mg, Funiculus umbilicalis suis D6 2 mg, Embryo totalis suis D6 2 mg, Placenta totalis suis D6 2 mg, Solanum dulcamara D3 10 mg, Symphytum officinale D6 10 mg, Nadidum D8 2 mg, Coenzyme A D8 2 mg, Sanguinaria canadensis D4 3 mg, Natrium diethyloxalaceticum D8 2 mg, Acidum DL-alpha liponicum D8 2 mg, Rhus toxicodendron D2 10 mg, Arnica montana D4 200 mg, Sulfur D6 3.6 mg.

    Ointment: 100 g containing: Cartilago suis D2, Funiculus umbilicalis suis D2, Embryo suis D2, Placenta suis D2 0.001 g each; Rhus toxicodendron D2 0.270 g; Arnica montana D2 0.3 g; Solanum dulcamara D2 0.075 g; Symphytum officinale D8 0.75 g; Sanguinaria canadensis D2 0.225 g; Sulfur D6 0.27 g; Nadidum D6, Coenzyme A D6, Acidum DL-alpha liponicum D6, Natrium diethyloxalaceticum D6 0.01 g each; Acidum silicicum D6 1.0 g.

    Ointment base: Hydrophilic ointment (DAB 10) containing: emulsifying cetostearyl alcohol (type A), ethanol, purified water, liquid paraffin, white soft paraffin, preserved with 12.8 vol.-% alcohol.


    Indications:

    Arthrosis/osteoarthritis, in particular knee arthrosis, polyarthrosis, spondylarthrosis, rotator cuff syndrome. Rheumatic joint diseases.


    Contraindications:

    Known allergy (hypersensitivity) to one or more of the ingredients. Do not use during pregnancy and lactation.


    Side effects:

    Tablets, injection solution: Allergic (hypersensitivity) skin reactions may occur in very rare cases (i.e. affects less than 1 in 10,000 users).


    Interactions with other medication:

    None known.


    Dosage:

    Tablets – Standard dosage: Adults (and children 12 yrs. and older): 1 tablet to be dissolved in the mouth 3x daily. Acute or initial dosage: 1 tablet every ½ to 1 hr., up to 12x daily, then continue with standard dosage.

    Injection solution – Standard dosage: Adults and children 12 yrs. and older: 1 ampoule 1 to 3x weekly. May be administered by s.c., i.d., i.m., i.a. or i.v. route. Acute or initial dosage: 1 ampoule daily, then continue with standard dosage.

    Ointment – Standard dosage: Adults (and children 12 yrs. and older): Apply 2 to 4x daily. For external use only. Apply a thin layer over the affected area.


    Package sizes:

    • Tablets: Packs containing 50 and 250 tablets. (9757)
    • Injection solution: Packs containing 10 and 100 ampoules of 2.0 ml each. (8705)
    • Ointment: Tubes containing 50 and 100 g of ointment. (9588)


    Clinical notes:

    Zeel may protect against aspects of cartilage damage. The chondrocyte, which is the “control center” of the cartilage, regulates the oscillatory cycle of tissue destruction and regeneration, influenced by IL-6, IL-1, and TNF-α. These cytokines affect matrix metalloproteinases and synthesis of other substances. The regenerative cycle is supported by transforming growth factor-β and plant-based ingredients in Zeel.

    Zeel’s ingredients such as sulfur and cartilage-based tissue materials (e.g., Cartilago suis and Funiculus umbilicalis suis) may support connective tissue regeneration and modulate inflammation.

    References

    1. Clarke JH. A Dictionary of Practical Materia Medica. Vol 1–3. 3rd ed. Bradford, England: Health Science Press; 1977.
    2. Hering C. The Guiding Symptoms of Our Materia Medica. Vol 1–10. 1st ed. New Delhi, India: Jain Publishers Ltd; 1989.
    3. Murphy R. Homeopathic Medical Repertory: A Modern Alphabetical Repertory. 1st ed. Pagaso Springs, CO: Hahnemann Academy of North America; 1993.
    4. Schroyens F. Synthesis: Repertorium Homeopathicum Syntheticum. 9th ed. London, England: Homeopathic Book Publishers; 2004.
    5. Allen TF. The Encyclopedia of Pure Materia Medica: A Record of the Positive Effects of Drugs Upon the Healthy Human Organism. Vol 1–12. 1st ed. Ridgewood, NJ: Gregg Press Inc; 1964.
    6. Allen TF. Handbook of Materia Medica and Homeopathic Therapeutics. 1st ed. New Delhi, India: Jain Publishers Ltd; 1889.
    7. Boericke W. Pocket Manual of Homoeopathic Materia Medica With Repertory, Comprising the Characteristic and Guiding Symptoms of All Remedies. 9th ed. Santa Rosa, CA: Boericke & Tafel; 1927.
    8. Burt WH. Physiological Materia Medica. 5th ed. Chicago, IL: Gross & Delbridge; 1896.
    9. Gibson DM. Studies of Homeopathic Remedies. 1st ed. Beaconsfield, England: Beaconsfield Publishers Ltd; 1987.
    10. Hoyne TS. Clinical Therapeutics. Vol 1–2. New Delhi, India: Jain Publishers Ltd; 1979.
    11. Hughes R, Dake JP. A Cyclopaedia of Drug Pathogenesis. Vol 1–4. 1st ed. New Delhi, India: World Homoeopathic Links; 1891.
    12. Kent JT. Lectures on Homeopathic Materia Medica. 4th ed. London, England, New York, NY, Philadelphia, PA: Boericke & Tafel; 1946.
    13. Kulkarni S. Gynaecologic and Obstetric Therapeutics. 1st ed. New Delhi, India: Jain Publishers Ltd; 1994.
    14. Lilienthal S. Homeopathic Therapeutics. 5th ed. Calcutta, India: Sett Dey & Co; 1925.
    15. Morrison R. Desktop Companion to Physical Pathology. 1st ed. Albany, CA: Hahnemann Clinic Publishing; 1998.
    16. Allen HC. Keynotes and Characteristics With Comparisons of Some of the Leading Remedies of the Materia Medica. 1st ed. Wellingborough, England: Thorsons Publishers Ltd; 1987.
    17. Allen HC. The Therapeutics of Intermittent Fever. 2nd ed. New Delhi, India: Jain Publishers Ltd; 1884.
    18. Blackwood AL. A Manual of Materia Medica, Therapeutics and Pharmacology (With Clinical Index). 2nd ed. New Delhi, India: World Homoeopathic Links; 1922.
    19. Choudhuri NM. A Study on Materia Medica and Repertory. 2nd ed. New Delhi, India: Jain Publishers Ltd; 1988.
    20. Cleveland CL. Salient Materia Medica and Therapeutics. 1st ed. New Delhi, India: Jain Publishers Ltd; 1888.
    21. Degroote F. Physical Examination and Observations in Homoeopathy. 1st ed. Gent, Belgium: Homoeoden Bookservice; 1992.
    22. Dewey WA. Practical Homeopathic Therapeutics. 3rd ed. Philadelphia, PA: Boericke & Tafel; 1934.
    23. Douglass MF. Pearls of Homeopathy. 1st ed. New Delhi, India: Jain Publishers Ltd; 1903.
    24. Farrington EA. The Clinical Materia Medica Being a Course of Lectures Delivered at the Hahnemann Medical College, of Philadelphia. 2nd ed. Philadelphia, PA: Hahnemann Publishing House; 1900.
    25. Farrington EA. Lesser Writings With Therapeutic Hints. 1st ed. Calcutta, India: Salzer & Co; 1935.
    26. Mohanty N. Text-Book of Homoeopathic Materia Medica. 1st ed. New Delhi, India: Jain Publishers Ltd; 1997.
    27. Royal G. Textbook of Homoeopathic Materia Medica. 1st ed. Calcutta, India: Roy Publishing House; 1920.
    28. Murphy R. The Homeopathic Remedy Guide: 1200 Homeopathic and Herbal Remedies. 1st ed. Blacksburg, VA: HANA Press; 2000.
    29. Vermeulen F. Concordant Materia Medica. 2nd ed. Haarlem, the Netherlands: Merlijn Publishers; 1997.
    30. Phatak SR. Materia Medica of Homeopathic Medicines. 1st ed. London, England: Foulke-Vaughan Publishers; 1988.
    31. Dunham C. Lectures on Materia Medica. 3rd ed. London, England, New York, NY, Philadelphia, PA: Boericke & Tafel; 1934.
    32. Vermeulen F. Synoptic Materia Medica. Vol 1. 6th ed. Haarlem, the Netherlands: Merlijn Publishers; 2000.
    33. Hahnemann S. Materia Medica Pura. Vol 1–2. 1st ed. London, England: Homeopathic Book Publishers; 1800.
    34. Hahnemann S. The Chronic Diseases, Their Peculiar Nature and Their Homoeopathic Cure. Tafel LH, trans-ed. Vol 1–2. 2nd ed. New Delhi, India: Jain Publishers Ltd; 1981.
    35. Wheeler CE. An Introduction to the Principles and Practice of Homoeopathy. 3rd ed. Saffron Walden, England: CW Daniel Co Ltd; 1948.
    36. Hughes R. Manual of Homoeopathic Pharmacodynamics. 5th ed. London, England: Leath & Ross; 1886.
    37. Boer CRM. A Synoptic Key of the Materia Medica. 1st ed. New Delhi, India: Jain Publishers Ltd; 1931.
    38. Buck H. The Outlines of Materia Medica and a Clinical Dictionary. 1st ed. New Delhi, India: Jain Publishers Ltd; 1865.
    39. Burt WH. Characteristic Materia Medica. 1st ed. New Delhi, India: Jain Publishers Ltd; 1978.
    40. Farrington EA. Comparative Materia Medica. 3rd ed. New Delhi, India: Jain Publishers Ltd; 1983.
    41. Farrington EA. Clinical Materia Medica Being a Course of Lectures Delivered at the Hahnemann Medical College, of Philadelphia. 2nd ed. Philadelphia, PA: Hahnemann Publishing House; 1900.
    42. Lippe A. Keynotes and Red Line Symptoms of Materia Medica. New Delhi, India: Jain Publishers Ltd; 1998.
    43. Allen MF. Special Symptomatology of the New Remedies. New Delhi, India: Jain Publishers Ltd.
    44. Allen TF. A Primer of Materia Medica for Practitioners of Homoeopathy. 1st ed. Philadelphia, PA: Boericke & Tafel; 1892.
    45. Reinhart E. Suis-Orgnpräparate in der Homotoxikologie. 1st ed. Baden-Baden, Germany: Aurelia Verlag; 1994.
    46. Reckeweg H-H. Homoeopathia Antihomotoxica–Symptomen- und Modalitätenverzeichnis mit Arzneimittellehre. Vol 1–2. 6th ed. Baden-Baden, Germany: Aurelia Verlag; 1999.
    47. Schmidt F, Baumgärtel A. Antihomotoxische Medizin–Band II: Homöopathische Antihomotoxica. Vol 2. 1st ed. Baden-Baden, Germany: Aurelia Verlag; 1996.
    48. Gupta RL. Director of Diseases and Cures in Homoeopathy: 1500 Authoritative References With Causes & Symptoms. Vol 1–2. 1st ed. New Delhi, India: Jain Publishers Ltd; 1989.
    49. Rastogi DP. Homoeopathic Gems. 2nd ed. New Delhi, India: Jain Publishers Ltd; 1993.
    50. Vermeulen F. Synoptic Materia Medica Illustrated–Similarities and Parallels Between Substance and Remedy. 2nd ed. Haarlem, the Netherlands: Merlijn Publishers; 2002.
    51. Plotnik M, Siman R. Biomodulation of osteoarthritis. J Biomed Ther. 2008;2:47–4.

  • Detox Kit

    Indications:
    For relief of symptoms of illness caused by an unhealthy lifestyle (substance abuse or unbalanced diet) and/or exposure to environmental toxins (pollution, pesticides or allergens). Promotes detoxification.

    Ingredients:

    Nierentropfen Berberis Cosmoplex
    Oral drops: Berberis vulgaris Dil. D3 1.0 ml, Solidago virgaurea Dil. D3 1.0 ml, Lytta vesicatoria Dil. D5 0.8 ml

    Lymphomyosot®
    Oral drops: Each 100 ml contains: Geranium robertianum D4 (diarrhea; hemorrhages), Nasturtium aquaticum D4 (gastric disorders; stomatitis), Ferrum iodatum D12 (glandular enlargement; emaciation) 10 ml each; Juglans regia D3 (sharp occipital pain; facial acne), Myosotis arvensis D3 (chronic bronchitis; vomiting during cough), Scrophularia nodosa D3 (eczema of ear; scrofulous swelling), Teucrium scorodonia D3 (chronic rhinitis and bronchitis), Veronica officinalis D3 (chronic bronchitis; pruritus), Equisetum hyemale D4 (sharp burning pain in urethra while urinating), Fumaria officinalis D4 (hepatic disorders; eczema), Natrum sulphuricum D4 (asthma; symptoms worse in rainy weather), Pinus sylvestris D4 (stiffness; cramps in calves), Gentiana lutea D5 (ravenous hunger; nausea; stomach ache), Aranea diadema D6 (diarrhea; susceptibility to dampness and cold), Sarsaparilla D6 (colic with backache; cystitis), Calcarea phosphorica D12 (joint stiffness and pain, worse with changes of weather), Thyroidinum D12 5 ml each. Contains ethyl alcohol 25% by volume.

    Nux vomica-Homaccord®
    Oral drops: Each 100 ml contains: Colocynthis D3, D10, D30, D200 (agonizing pain in abdomen causing patient to bend over double), Lycopodium clavatum D3, D10, D30, D200, D1000 (abdomen is bloated immediately after a light meal) 0.3 ml each; Bryonia alba D3, D6, D10, D15, D30, D200, D1000 (pressure in stomach after eating; nausea and faintness when rising up), Nux vomica D3, D10, D15, D30, D200, D1000 (weight and pain in stomach worse after eating; stomach very sensitive to pressure) 0.2 ml each. Contains ethyl alcohol 25% by volume.

    Dosage:
    Adults and children above 11 years: Pour thirty drops of each bottle into a bottle of water and consume in one day. A physician should be consulted before using in children under 12 years of age.

    Dosage forms:
    Oral drops: Three dropper bottles containing 30ml each.

  • Citric Acid Cycle

    Injection Solutions

    Composition: 1 combination pack (10 ampoules of 1.1 ml) contains 1 ampoule each of:

    • Magnesium-manganum-phosphoricum-Injeel
    • Natrium pyruvicum-Injeel
    • Natrium oxalaceticum-Injeel
    • Acidum citricum-Injeel
    • Acidum cis-aconiticum-Injeel
    • Baryum oxalsuccinicum-Injeel
    • Acidum alpha-ketoglutaricum-Injeel
    • Acidum succinicum-Injeel
    • Acidum fumaricum-Injeel
    • Acidum DL-malcium-Injeel

    All diseases classified as cellular phases (degeneration phases, dedifferentiation phases) and which are consequently characterized by defective enzymatic control, blockages, and/or defective cellular oxidation, eg:

    • Paresis, neuralgia, toxic neuritis, vegetative dystonia, migraine.
    • Dermatosis, neurodermitis, pruritus (including pruritus vulvae), psoriasis, vitiligo, pemphigus.
    • Bronchial asthma.
    • Gastric and duodenal ulcer, hepatosis, cirrhosis of the liver and injurious hepatic disorders, pancreatopathy.
    • Nephropathy (eg, nephrosis and chronic nephritis).
    • Myocardial impairment, angina-like symptoms, adjunctive treatment subsequent to myocardial infarction, arteriosclerosis, cerebral sclerosis.
    • Dysfunction and dysregulation of endocrine glands (eg, diabetes mellitus, dysthyroidism).
    • Precancerous and dedifferentiation phases (previously: neoplasm phases) within any tissue whatsoever.
    • During and subsequent to X-rays and exposure to ionizing radiation; several enzymes (eg, the malate dehydrogenases) are especially sensitive.
    • Thrombocytopenia, leukopenia.

    Dosage: The injections are generally applied 1–2 times weekly. Upon completion of a series (ie, after 4 combination injections, see below), therapy with bioregulatory metabolic factors may possibly require interpolation by a treatment-free interval of 2 to 4 weeks until the injections’ effects have subsided.

    Plan of subcutaneous injections:
    Injection 1:

    • Magnesium-manganum-phosphoricum-Injeel
    • Natrium pyruvicum-Injeel
    • Natrium oxalaceticum-Injeel

    Injection 2:

    • Acidum citricum-Injeel
    • Acidum cis-aconiticum-Injeel

    Injection 3:

    • Baryum oxalsuccinicum-Injeel
    • Acidum alpha-ketoglutaricum-Injeel

    Injection 4:

    • Acidum succinicum-Injeel
    • Acidum fumaricum-Injeel
    • Acidum DL-malcium-Injeel

    After an application-free interval of 2 to 4 weeks, repeat this series of injections. Each acid and/or its salt may be injected separately and repetitively in the Injeel-forte form as well. This is indicated primarily when a particularly effective action during one of the combined injections listed above (1 to 4) was achieved. The ampoules contained in this combination should subsequently be applied individually.

    Package size: Combination pack containing 10 ampoules of 1.1 ml each. (8596, 8945, 8595, 8598, 8599, 8942, 8614, 9203, 8668, 8670)

    Pharmacoclinical notes

    Magnesium-manganum-phosphoricum-Injeel
    Magnesium: classified as an ion; neuroprotective after traumatic brain injury¹; protects against oxidative endothelial cytotoxicity by inhibiting lipid peroxidation, formation of OH radicals and H₂O₂²; peroxidized deoxyribose degradation³; magnesium is the second most abundant intracellular cation (after sodium) and has many important roles to play in cell biology, including the synthesis of essential molecules (eg, glutathione, DNA, RNA, proteins, and carbohydrates), structural roles (in bone, cell membranes, and chromosomes), function of certain enzymes, transport of certain ions across the membrane, supporting the production of adenosine triphosphate (ATP), cell signalling, and cell migration (for wound healing)⁴; acts as an important antioxidant (especially protecting the mitochondria) and affects aging⁵; deficiencies are associated with development of kidney stones, atherosclerosis, diabetes mellitus⁶, cardiometabolic syndrome⁷, chronic kidney disease⁸, cardiovascular disease⁹, poor-quality sleep¹⁰ and other pathological conditions, such as obesity, associated with low levels of chronic inflammatory stress¹¹; supplementation at therapeutic doses can be beneficial for many different clinical conditions, including reducing the mortality of myocardial infarctions (if administered parenterally in early stages)¹² and subarachnoid hemorrhages¹³, prophylaxis of migraine (especially for children and migraine related to menstruation)¹⁴, depression (especially if treatment resistant)¹⁵, osteoporosis¹⁶, and treatment of eclampsia-preeclampsia and acute¹⁷ and chronic asthma¹⁸; hypomagnesemia contributes to the development of many different potential conditions, including leg cramps, palpitations, cardiac arrhythmias, and intestinal inflammation¹⁹.

    Natrium pyruvicum-Injeel (sodium pyruvate; pyruvic acid, sodium salt): classified as an intermediate compound (termed a keto-acid) in the metabolism of carbohydrates, proteins, and fats²⁰; produced from phosphoenolpyruvate in the end stages of glycolysis and, depending on metabolic conditions, can be reduced to lactate (by lactate dehydrogenase) in the cytosol or oxidatively decarboxylated to acetyl coenzyme A (CoA, by pyruvate dehydrogenase complex in the mitochondria)²¹; if there is a deficiency of thiamine (vitamin B1), it is not oxidized properly and can accumulate in tissues, such as in nervous system tissues; hypertonic solutions can provide protection against inflammatory and oxidative stress and in preventing liver injury after hemorrhagic shock³; might prevent oxidative stress to the retina by acting as a reactive oxygen species scavenger and metabolic agonist²²; might have therapeutic potential in mitochondrial diseases²³; topical agent might have use as a treatment for mild-to-moderate papulopustular acne²⁴; preserves metabolic effects produced by hypoxia in glioma and hepatoma cell cultures²⁵; protects neurons against N-methyl-D-aspartate-induced neurotoxicity, possibly by reducing the accumulation of glutamate²⁶; marketed as an ergogenic agent to improve exercise capacity, increase weight and fat loss, act as an antioxidant, and lower plasma lipids, although there is a need for further studies²⁷; also might play a role in supporting the function of neutrophils by helping maintain their endogenous supply of amino acids for fuel²⁸.

    (The pharmacoclinical notes continue in the same format for the remaining constituents: Natrium oxalaceticum-Injeel; Acidum citricum-Injeel; Acidum cis-aconiticum-Injeel; Baryum oxalsuccinicum-Injeel; Acidum alpha-ketoglutaricum-Injeel; Acidum succinicum-Injeel; Acidum fumaricum-Injeel; Acidum DL-malcium-Injeel.)

    For further information on the single-constituent medications in the combination pack, see Chapter 2, “Single-Constituent Homeopathic Medications in Potency Chords.”

    References

    1. Turner RJ, Dasilva KW, O’Connor C, van den Heuvel C, Vink R. Magnesium chloride offers no more protection than magnesium sulphate following diffuse traumatic brain injury in rats. J Am Coll Nutr. 2004;23(5):541S–544S.
    2. Mak IT, Koromazov AM, Kramer HH, Weigel WB. Protective mechanisms of Mg-pyruvate against oxidative endothelial cytotoxicity. Cell Mol Biol (Noisy-le-grand). 2000;46:813–1344.
    3. Hogdon J, Drake VJ. Magnesium. http://pro.gastroenterology.net/yellow/rest/minerals/magnesium/index.html. Updated August 2007. Accessed January 17, 2011.
    4. Barbagallo M, Dominguez LJ. Magnesium and aging. Curr Pharm Des. 2010;16(7):832–839.
    5. Musso CC. Magnesium metabolism in health and disease. Int J Nutr Nephrol. 2009;41(2):357–362.
    6. Khanipelly M, Goldsmith DJ, Uyar ME, Turgut F, Cozza A. Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif. 2010;29(3):280–292.
    7. Mathers TW, Beckstrand RL. Oral magnesium supplementation in adults with coronary heart disease: current status of serum and dietary sources. Nutr Clin Pract. 2009;21(6):651–697.
    8. Heidker EH, Johnson KJ, Zarling AJ. Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in athletes. Med Sci Sports. 2010;23(4):158–168.
    9. Nielsen FH. Magnesium, nutrition, and obesity. Nutr Rev. 2010;68(6):333–340.
    10. Golnar et al. Nutritional management for acute myocardial infarction. Intern Med Rev. 2010;15(2):113–121.
    11. Van den Berg WM. Magnesium in subarachnoid hemorrhage: proven benefit. CMAJ. 2010;183(10):283.
    12. Schupelphard H, et al. Postcardial Gabbarti I, Rolando S, Terri MG. Benefiting C. non-pharmaceutical approach to migraine prophylaxis: part II. Neurol Sci. 2010;31(suppl 1):s137–s139.
    13. Elazor GA Jr, Boyd KL. Magnesium for treatment-resistant depression: a review and hypothesis. Med Hypotheses. 2010;74(4):649–660.
    14. Meheller AC, Singer RR, Gruber RH, DeLosa ML. The effect of Mg in migraine. Headache. 2010;39(2):131–141.
    15. Eeusdar, Yoe. Lithium treatment. J Electrocardiol. 2010;29(2):131–141.
    16. Muhl A, Tsiang H, Nicodemius KA, et al. Effects of alpha-ketoglutarate on retinoceptor network and ROS production. Ann Nutr Metab. 2011;59:124–130.
    17. Bunik VI, Fernie AR. Metabolic control exerted by the 2-oxoglutarate dehydrogenase reaction: a cross-linkage between energy production and nitrogen assimilation. Biochem J. 2009;422(3):405–421.
    18. Harirson AP. Piezowski SG. Biological effects of 2-oxoglutarate with particular emphasis on the regulation of protein, mineral and lipid absorption. J Physiol Pharmacol. 2008;59(suppl 1):91–106.
    19. Syrobor LA. The use of alpha-ketoglutarate salts in clinical nutrition and metabolic care. Curr Opin Clin Nutr Metab Care. 1999;2(1):33–37.
    20. Succinate acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=110 Accessed February 8, 2011.
    21. Kharzov VA, Kiselal AA, Vasiliev KY. Chernysheva GA. Cardioprotective effects of trimetazidine in a combination of succinic and malic acids during acute myocardial ischemia. Bull Exp Biol Med. 2008;146(2):218–222.
    22. Mazey EE, Paskov AB, Uchitel MI, et al. A succinate-based composition based on succinic–malic acid mixture for correction of mitochondrial dysfunction. Biochemistry (Mosc). 2007;72(10):947–950.
    23. Acyl et al. Role of gamma-aminobutyric acid in succinate-induced attenuation of metabolic acidosis. Clin Chem. 2009;55(10):1910–1916.
    24. Gurvitch AM, Mustukina EA, Zarutskaya VV, et al. Prophylaxis of encephalopathies and risk factors of atherogenesis development in the postresuscitation period. Vestn Ross Akad Med Nauk. 2008;6:65–71.
    25. Fumaric acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=449472&loc=ec_rcs. Accessed February 8, 2011.
    26. Brewer LR, Rogers SJ. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol. 2007;32(3):246–249.
    27. Saccharin Q, Koch HJ. Long-term treatment of psoriasis using fumaric acid esters. Br J Dermatol. 1999;141:110–115.
    28. Garcia-Caballero M, Mari-Belfa M, Medina MA, Quesada AR. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antioxidant properties. Pharmacol Res. 2008;58(3):395–401.
    29. DITCH et al. Fumaric acid esters: clinical and experimental background. Dermatology. 1998;196(suppl 2):7–12.
    30. Huse R, Callea M. Metabolism of mass spectrometry of succinate in patients with multiple sclerosis. Trace Elem Res. 2005;112(1):18–22.
    31. Wolany H, Kolnikowski T. Therapeutic relevance of succinic–malic acid in metabolic syndrome. J Clin Endocrinol Metab. 2003;88(2):545–552.
    32. Nagy D, Marosi M, Kis Z, et al. Oxaloacetate decreases the infarct size and attenuates the reduction in evoked responses after photothrombotic focal ischemia in the rat cortex. Cell Mol Neurobiol. 2009;29(6-7):827–835.
    33. Citric acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=311&loc=ec_rcs. Accessed February 8, 2011.
    34. The citric acid cycle. In: Nelson DL, Cox MM, eds. Lehninger Principles of Biochemistry. 5th ed. New York, NY: WH Freeman; 2008:615–641.
    35. Nagar R, Ragai M, Shimaski N, Baynes WJ, Fujiwara I. Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type I) diabetic rats. Biochem Biophys Res Commun. 2010;393(1):118–122.
    36. Baynes JW, Murray B. The metal chelators, triennate and citrate, inhibit the development of diabetic pathology in the Zucker diabetic rat. Exp Diabetes Res. 2009;2009:696378.
    37. Kosa N, Atyapcui BN, Yilmaz N, et al. Citric acid as a decalcifying agent for the excised calcified human heart valves. Anatol J Cardiol Derg. 2008;8(2):94–98.
    38. Cis-aconitate: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5459816&loc=ec_rcs. Accessed February 8, 2011.
    39. Ricciardolo FL. Mechanisms of citric and induced bronchoconstriction. Am J Med. 2001;111(suppl A8):18S–24S.
    40. Kar S, Kar B, Bhattacharya PK, Ghosh DK. Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy. Antimicrob Agents Chemother. 1993;37(11):2459–2465.
    41. Oxalosuccinic acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=912&loc=ec_rcs. Accessed February 8, 2011.
    42. Alpha-ketoglutarate acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=164533&loc=ec_rcs. Accessed February 8, 2011.
    43. Leimer J, Mindlau Y, Auger C, et al. Acquisicio AA, Appanna VP, Appanna VD. Histidine is a source of the antioxidant, alpha-ketoglutarate, in Pseudomonas fluorescens challenged by oxidative stress. FEMS Microbiol Lett. 2010;309(2):170–177.
    44. Mallouki R, Berkary L, Leriner J, et al. The tricarboxylic acid cycle, an ancient metabolic network with a new dimension. PLoS One. 2007;2(8):e890.
    45. Muhling J, Tusing F, Nicodemius KA, et al. Effects of alpha-ketoglutarate on glutathione and amino acid biosynthesis and ROS production. Amino Acids. 2010;38(1):167–177.
    46. Bunik VI, Fernie AR. Metabolic control exerted by the 2-oxoglutarate dehydrogenase reaction: a cross-talk between energy production and nitrogen assimilation. Biochem J. 2009;422(3):405–421.
    47. Harrison AP. Piezowski SG. Biological effects of 2-oxoglutarate with particular emphasis on the regulation of protein, mineral and lipid absorption. J Physiol Pharmacol. 2008;59(suppl 1):91–106.
    48. Gurvitch AM, Mustukina EA, Zarutskaya VV. et al. Prophylaxis of encephalopathies and risk factors of atherogenesis development in the postresuscitation period. Vestn Ross Akad Med Nauk. 2008;6:65–71.
    49. Fumaric acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=449472&loc=ec_rcs. Accessed February 8, 2011.
    50. Brewer LR, Rogers SJ. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol. 2007;32(3):246–249.
    51. Saccharin Q, Koch HJ. Long-term treatment of psoriasis using fumaric acid esters. Br J Dermatol. 1999;141:110–115.
    52. Garcia-Caballero M, Mari-Belfa M, Medina MA, Quesada AR. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antioxidant properties. Pharmacol Res. 2008;58(3):395–401.
    53. Lutz M, Lyall B, Moser DG, et al. Pharmacology of succinic acid derivatives. Ther Adv Neurol Disord. 2010;3(2):53–60.
    54. Nagy D, Marosi M, Kis Z, et al. Oxaloacetate decreases the infarct size and attenuates the reduction in evoked responses after photothrombotic focal ischemia in the rat cortex. Cell Mol Neurobiol. 2009;29(6-7):827–835.
    55. Citric acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=311&loc=ec_rcs. Accessed February 8, 2011.
    56. The citric acid cycle. In: Nelson DL, Cox MM, eds. Lehninger Principles of Biochemistry. 5th ed. New York, NY: WH Freeman; 2008:615–641.
    57. Nagar R, Ragai M, Shimaski N, Baynes WJ, Fujiwara I. Citric acid inhibits development of cataracts, proteinuria and ketosis in streptozotocin (type I) diabetic rats. Biochem Biophys Res Commun. 2010;393(1):118–122.
    58. Baynes JW, Murray B. The metal chelators, triennate and citrate, inhibit the development of diabetic pathology in the Zucker diabetic rat. Exp Diabetes Res. 2009;2009:696378.
    59. Kosa N, Atyapcui BN, Yilmaz N, et al. Citric acid as a decalcifying agent for the excised calcified human heart valves. Anatol J Cardiol Derg. 2008;8(2):94–98.
    60. Cis-aconitate: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5459816&loc=ec_rcs. Accessed February 8, 2011.
    61. Ricciardolo FL. Mechanisms of citric and induced bronchoconstriction. Am J Med. 2001;111(suppl A8):18S–24S.
    62. Kar S, Kar B, Bhattacharya PK, Ghosh DK. Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy. Antimicrob Agents Chemother. 1993;37(11):2459–2465.
    63. Oxalosuccinic acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=912&loc=ec_rcs. Accessed February 8, 2011.
    64. Alpha-ketoglutarate acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=164533&loc=ec_rcs. Accessed February 8, 2011.
    65. Leimer J, Mindlau Y, Auger C, et al. Acquisicio AA, Appanna VP, Appanna VD. Histidine is a source of the antioxidant, alpha-ketoglutarate, in Pseudomonas fluorescens challenged by oxidative stress. FEMS Microbiol Lett. 2010;309(2):170–177.
    66. Mallouki R, Berkary L, Leriner J, et al. The tricarboxylic acid cycle, an ancient metabolic network with a new dimension. PLoS One. 2007;2(8):e890.
    67. Muhling J, Tusing F, Nicodemius KA, et al. Effects of alpha-ketoglutarate on glutathione and amino acid biosynthesis and ROS production. Amino Acids. 2010;38(1):167–177.
    68. Bunik VI, Fernie AR. Metabolic control exerted by the 2-oxoglutarate dehydrogenase reaction: a cross-talk between energy production and nitrogen assimilation. Biochem J. 2009;422(3):405–421.
    69. Harrison AP, Piezowski SG. Biological effects of 2-oxoglutarate with particular emphasis on the regulation of protein, mineral and lipid absorption. J Physiol Pharmacol. 2008;59(suppl 1):91–106.
    70. Gurvitch AM, Mustukina EA, Zarutskaya VV, et al. Prophylaxis of encephalopathies and risk factors of atherogenesis development in the postresuscitation period. Vestn Ross Akad Med Nauk. 2008;6:65–71.
    71. Fumaric acid: compound summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=449472&loc=ec_rcs. Accessed February 8, 2011.
    72. Brewer LR, Rogers SJ. Fumaric acid esters in the management of severe psoriasis. Clin Exp Dermatol. 2007;32(3):246–249.
    73. Saccharin Q, Koch HJ. Long-term treatment of psoriasis using fumaric acid esters. Br J Dermatol. 1999;141:110–115.
    74. Garcia-Caballero M, Mari-Belfa M, Medina MA, Quesada AR. Dimethylfumarate inhibits angiogenesis in vitro and in vivo: a possible role for its antioxidant properties. Pharmacol Res. 2008;58(3):395–401.

  • Zeel®

    Zeel® ad us. vet. Injection Solution 5.0 ml Tablets

    Zeel® T Injection Solution 2.0 ml – Tablets – Ointment

    Composition:

    Zeel ad us. vet. injection solution: 1 ampoule of 5 ml contains: Cartilago suis D6 5 µl; Funiculus umbilicalis suis D6 5 µl; Embryo suis D6 5 µl; Placenta suis D6 5 µl; Solanum dulcamara D3 25 µl; Symphytum officinale D6 25 µl; Nadidum D8 5 µl; Coenzymum A D8 5 µl; Sanguinaria canadensis D4 7.5 µl; Arnica montana D3 50 µl; Sulfur D6 9 µl; Natrium diethyloxalaceticum D8 5 µl; Acidum alpha-liponicum D8 5 µl; Rhus toxico- dendron D2 25 µl.

    Zeel ad us. vet. tablets: 1 tablet cont.: Cartilago suis D6 15 mg; Funiculus umbilicalis suis D6 15 mg; Embryo suis D6 15 mg; Placenta suis D6 15 mg; Toxicodendron querci- folium D3 30 mg; Arnica montana D4 60 mg; Solanum dulcamara D3 20 mg; Symphy- tum officinale D8 20 mg; Sanguinaria canadensis D4 30 mg; Sulfur D6 40 mg; Nadi- dum D6 10 mg; Coenzymum A D6 10 mg; Acidum alpha-liponicum D6 10 mg; Natrium diethyloxalaceticum D6 10 mg. Zeel T injection solution: 2.0 ml (= 2.0 g) cont.: Cartilago suis D6 2 mg, Funiculus um- bilicalis suis D6 2 mg, Embryo suis D6 2 mg, Placenta suis D6 2 mg, Solanum dulca- mara D3 10 mg, Symphytum officinale D6 10 mg, Nadidum D8 2 mg, Coenzymum A D8 2 mg, Sanguinaria canadensis D4 3 mg, Natrium diethyloxalaceticum D8 2 mg, Acidum alpha-liponicum D8 2 mg, Toxicodendron quercifolium D2 10 mg, Arnica montana D4 200 mg, Sulfur D6 3.6 mg.

    Zeel T tablets: 1 tablet cont.: Cartilago suis D4 0.3 mg, Funiculus umbilicalis suis D4 0.3 mg, Embryo suis D4 0.3 mg, Placenta suis D4 0.3 mg, Toxicodendron quercifolium D2

    0.54 mg, Arnica montana D1 0.6 mg, Solanum dulcamara D2 0.15 mg, Symphytum officinale D8 0.15 mg, Sanguinaria canadensis D3 0,45 mg, Sulfur D6 0.54 mg, Nadi- dum D6 0.03 mg, Coenzymum A D6 0.03 mg, Natrium diethyloxalaceticum D6 0.03 mg, Acidum alpha-liponicum D6 0.03 mg, Acidum silicicum D6 3 mg.

    Zeel T ointment: 100 g cont.: Cartilago suis D2, Funiculus umbilicalis suis D2, Embryo suis D2, Placenta suis D2 0.001 g each; Toxicodendron quercifolium D2 0.27 g; Arnica montana D2 0.3 g; Solanum dulcamara D2 0.075 g; Symphytum officinale D8 0.75 g; Sanguinaria canadensis D2 0.225 g; Sulfur D6 0.27 g; Nadidum D6, Coenzym A D6, Acidum alpha-liponicum D6, Natrium diethyloxalaceticum D6 0.01 g each; Acidum si- licicum D6 1 g. Ointment base: hydrophilic ointment (DAB 10) cont.: emulsifying cetyl- stearyl alcohol, ethanol, purified water, viscous paraffin, white vaseline, preserved with

    12.9 vol.-% ethanol.

    Indications:

    Degenerative joint affections, e.g. arthrosis, spondylarthrosis, intervertebral disc dis- ease, bone spavin, arthrosis of the pastern joint, polyarthritis, joint galls, chronic ten- dovaginitis.

    Contraindications: Poison ivy and/or Arnica hypersensitivity. Because of the constitu- ent Sanguinaria (bloodroot) do not use during pregnancy and lactation. In case of exist- ing liver conditions or history thereof or simultaneous use of hepatotoxic substances use only after consultation with the physician.

    Side effects: (Zeel ad us. vet injection solution): Hypersensitivity reactions (or even anaphylactic reactions) may occur in isolated instances on the i.v. administration of foreign proteins in a concentration higher than D10. (Zeel T injection solution): During the treatment with drugs containing bloodroot (Sanguinaria) alkaloids there have been individual reports of increased liver function enzymes (transaminases) and serum bi- lirubin elevations up to drug-induced jaundice (drug-related toxic hepatitis), which nor- malized or receded after discontinuation of the product. In very rare cases gastrointes- tinal complaints or skin reactions can occur – also some days after use. Temporarily, reddening, tumefaction and pain may occur on the puncture site.

    Interaction with other medications: None known.

    Waiting period: None.

    Instructions for use, route and duration of administration:

    Zeel ad us. vet. injection solution is to be administered by s.c., i.v. or periarticular injec- tion.

    According to species, the daily single dosage is as follows:

    Horse: 5 ml

    Large dog: 3–4 ml

    Medium dog: 2 ml

    Small dog: 1–2 ml

    Small pets: 0.5 ml

    For long-term treatment of chronic affections or those with tendencies to recur, the indicated single dosage can be administered at 4-day intervals.

    Zeel ad us. vet. tablets are to be administered orally. According to species, the daily single dosage is as follows:

    Large dog: 3 tablets 2–3 times

    Medium dog: 2 tablets 2–3 times

    Small dog, cat: 1 tablet 2–3 times

    Dosage:

    Zeel T injection solution 2.0 ml, Zeel T tablets, Zeel T ointment:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Zeel ad us. vet. injection solution: Packs containing 5 or 50 ampoules of 5.0 ml each. Zeel ad us. vet. tablets: Packs containing 100 or 500 tablets.

    Zeel T injection solution: Packs containing 10 or 50 ampoules of 2.0 ml each. Zeel T tablets: Packs containing 50 or 250 tablets. Zeel T ointment: Tubes containing 50 g.

  • Vertigoheel®

    Drops

    Tablets

    Composition:

    Drops: 100 g cont.: Anamirta cocculus D4 70 g; Conium maculatum D3, Ambra grisea D6, Petroleum rectificatum D8 10 g each. Contains 35 vol.-% alcohol.

    Tablets: 1 tablet cont.: Anamirta cocculus D4 210 mg; Conium maculatum D3, Ambra grisea D6, Petroleum rectificatum D8 30 mg each.

    Indications:

    Dizziness of various origins (e.g. car sickness)

    Contraindications: None known.

    Side effects: None known.

    Interaction with other medications: None known.

    Dosage:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Drops: Drop bottles containing 30 or 100 ml. Tablets: Packs containing 50 or 250 tablets.

  • Veratrum-Homaccord®

    Veratrum-Homaccord® ad us. vet. Injection Solution 5.0 ml

    Veratrum-Homaccord® Drops

    Composition:

    Veratrum-Homaccord ad us. vet. injection solution: 1 ampoule of 5.0 ml (= 5 g) contains: Veratrum album D4 30 mg; Veratrum album D10 30 mg; Veratrum album D30 30 mg; Veratrum album D200 30 mg; Aloe D4 10 mg; Aloe D10 10 mg; Aloe D30 10 mg; Potentilla erecta D10 5 mg; Potentilla erecta D30 5 mg; Rheum D10 5 mg; Rheum D30 5 mg; Potentilla erecta D2 5 mg; Rheum D2 5 mg.

    Veratrum-Homaccord drops: 100 g cont.: Veratrum album D2, Veratrum album D10, Veratrum album D30, Veratrum album D200 0.6 g each; Aloe D2, Aloe D10, Aloe D30

    0.2 g each; Tormentilla Ø 0.3 g; Tormentilla D10, Tormentilla D30 0.1 g each; Rheum D1 1.0 g; Rheum D10, Rheum D30 0.1g each. Contains 35 vol.-% alcohol.

    Indications:

    Acute nausea and diarrhea, gastroenteritis, feline panleukopenia, parvovirus-enteritis, acute and chronic central disorders due to heat, sunlight exposition, infections with collapse tendency.

    Contraindications: First trimenon of pregnancy.

    Side effects: None known.

    Interaction with other medications: None known.

    Waiting period: None.

    Instructions for use, route and duration of administration:

    Veratrum-Homaccord ad us. vet. is to be administered by s.c., i.m. or i.v. injection.

    According to species, the single dosage is as follows:

    Horse, cattle, swine: 5 ml

    Piglet: 2–3 ml

    Sheep, goat: 2 ml

    Large dog: 3–4 ml

    Medium dog: 2 ml

    Small dog, cat: 1–2 ml

    Puppy: 0.5–1 ml

    Small pets: 0.5 ml

    If necessary, depending on the severity of the case, the indicated dosage is to be re- peated after 3-4 hours.

    For long-term treatment of chronic affections, the indicated single dosage can be ad- ministered at intervals of 2-3 days.

    Dosage: Veratrum-Homaccord drops:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Injection solution: Packs containing 5 or 50 ampoules of 5.0 ml each. Drops: Drop bottles containing 30 and 100 ml.

  • Valerianaheel®

    Drops

    Composition:

    100 g cont.: Valeriana officinalis Ø 65 g; Humulus lupulus Ø, Crataegus Ø, Hypericum perforatum D1 5 g each; Melissa officinalis Ø 3 g; Chamomilla recutita Ø, Avena sativa Ø 2 g each; Acidum picrinicum D5 10 g; Kalium bromatum D1, Ammonium bromatum D1, Natrium bromatum D1 1 g each. Contains 66 vol.-% alcohol.

    Indications:

    As sedative in conditions of restlessness; neurasthenia.

    Contraindications: Pregnancy and lactation.

    Hypersensitivity to Chamomilla or other botanicals of the daisy (compositae) family as well as hypersensitivity to bromine.

    Side effects: Allergic skin reactions may occur in rare cases.

    Interaction with other medications: None known.

    Dosage:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Drop bottles containing 30 or 100 ml.

  • Ubichinon compositum

    Injection Solution 2.2 ml

    Composition:

    Injection solution: 2.2 ml (2.2 g) cont.: Ubichinonum D10, Acidum ascorbicum D6; Thiaminum hydrochloricum D6, Natrium riboflavinum phosphoricum D6, Pyridoxinum hydrochloricum D6; Nicotinamidum D6, Vaccininum myrtillus D4, Colchicum autum- nale D4, Podophyllum peltatum D4, Conium maculatum D4, Hydrastis canadensis D4, Acidum sarcolacticum D6, Hydrochinonum D8, Acidum alpha-liponicum D8, Sulfur D8, Manganum phosphoricum D8, Natrium diethyloxalaceticum D8, Trichinoylum D10, Anthrachinonum D10, Naphthochinonum D10, para-Benzochinonum D10, Adenosi- num triphosphoricum D10, Coenzymum A D10, Galium aparine D6, Acidum acetylo- salicylicum D10, Histaminum D10, Nadidum D10, Magnesium gluconicum D10 22 mg each.

    Indications:

    Stimulation of the defensive mechanisms against toxins in order to reactivate the blocked enzymatic systems in defective enzymatic functions and degenerative diseases (cellular phases).

    Contraindications: Do not use during pregnancy and lactation.

    Side effects: None known.

    Interaction with other medications: None known.

    Dosage:

    See chapter Dosage of Heel Medications in Veterinary Medicine, p. 17–20.

    Package sizes:

    Packs containing 10 or 50 ampoules of 2.2 ml each.